Work With Us
Peer Reviewed Publications
MIST Digital Library
Day 1 MIST 2023
Day 2 Video MIST 2023
Day 3 Video MIST 2023
Optimising HIV Research and Practice Impact in Resources
Universiti Malaya Annual Report
News and Media
Basic & Translational Science
Social & Behavioral Science
HIV and STIs
Secretariat, All Party Parliamentary Group Malaysia
WHO Tropical Disease Research Regional Training Centre
Harapan Community Clinic
Infectious Diseases Unit University Malaya
Strategic Timing of Anti-Retroviral Treatment (START Study)
The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...
Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...
AmFAR, Foundation for AIDS Research: Treat Asia HIV Observational Database (TAHOD)
TREAT Asia has pioneered the first database to assess the natural history of HIV disease in treated and untreated patients throughout Asia and the Pacific. In an unprecedented regional collaboration...
AmFAR, Foundation for AIDS Research: TAHOD Tuberculosis Study
The use of highly active antiretroviral therapy (HAART) has led to dramatic reductions in morbidity and mortality in HIV patients. However, tuberculosis (TB) remains a common opportunistic infections and a...
University of New South Wales: The Altair Study
Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed. This open label study randomly assigned treatment-naive, human immunodeficiency virus (HIV)—infected subjects to receive tenofovir-emtricitabine with efavirenz...